07.22.15
IlluminOss Medical has appointed Clive V. Ridgwell as vice president of sales. Ridgwell brings more than 30 years of commercial experience in medical device fields, which he will apply to the further development of IlluminOss’ product strategy in global markets.
Ridgwell spent the last 21 years at Zimmer (now Zimmer Biomet), where he worked in a number of senior executive roles within its European, Middle Eastern and African operations. Most recently, he served as vice president of the Trauma Division. Prior to that, he held the positions of vice president for the Spine Division and managing director and general manager of Zimmer UK, Nordic, Scandinavia and Southern Africa.
“Clive Ridgwell’s extensive operational expertise has proven fundamental to the development of medical device companies both at a geographical and product-specific level and we are pleased to welcome him to the IlluminOss team,” said Robert Rabiner, president and CEO of IlluminOss Medical. “He will be integral to the advancement of our commercialization strategy in Europe.”
The IlluminOss System is used as a minimally invasive treatment of complex orthopedic fractures. It has been used in more than a thousand patients in Europe, where it is commercially available and has been in clinical use since 2010. The technology is not yet commercially available in the United States.
Using a light-curable polymer, contained within an expandable balloon catheter, IlluminOss’ intramedullary patient-conforming implant achieves the repair and stabilization of fractures. This technology allows for fracture fixation through patient-specific intramedullary implants. The procedure is made through a small percutaneous surgical approach.
“I am excited to be part of a company with a groundbreaking technology that is well positioned to truly change the way fracture repair can be approached,” said Ridgwell. “I look forward to applying my cumulative career experience to advancing the successful adoption of the IlluminOss Systems in many international markets so patients and surgeons alike can reap the benefits of this new method.”
East Providence, R.I.-based IlluminOss Medical is privately held.
Ridgwell spent the last 21 years at Zimmer (now Zimmer Biomet), where he worked in a number of senior executive roles within its European, Middle Eastern and African operations. Most recently, he served as vice president of the Trauma Division. Prior to that, he held the positions of vice president for the Spine Division and managing director and general manager of Zimmer UK, Nordic, Scandinavia and Southern Africa.
“Clive Ridgwell’s extensive operational expertise has proven fundamental to the development of medical device companies both at a geographical and product-specific level and we are pleased to welcome him to the IlluminOss team,” said Robert Rabiner, president and CEO of IlluminOss Medical. “He will be integral to the advancement of our commercialization strategy in Europe.”
The IlluminOss System is used as a minimally invasive treatment of complex orthopedic fractures. It has been used in more than a thousand patients in Europe, where it is commercially available and has been in clinical use since 2010. The technology is not yet commercially available in the United States.
Using a light-curable polymer, contained within an expandable balloon catheter, IlluminOss’ intramedullary patient-conforming implant achieves the repair and stabilization of fractures. This technology allows for fracture fixation through patient-specific intramedullary implants. The procedure is made through a small percutaneous surgical approach.
“I am excited to be part of a company with a groundbreaking technology that is well positioned to truly change the way fracture repair can be approached,” said Ridgwell. “I look forward to applying my cumulative career experience to advancing the successful adoption of the IlluminOss Systems in many international markets so patients and surgeons alike can reap the benefits of this new method.”
East Providence, R.I.-based IlluminOss Medical is privately held.